New Equilibrium Biosciences utilizes artificial intelligence to analyze biophysical data, enabling structure-based design in drug development. This platform identifies potential molecular candidates more efficiently, addressing the challenge of time-consuming and costly traditional drug discovery methods.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods are time-consuming and costly, hindering the efficient identification of potential molecular candidates. Analyzing biophysical data to design effective drugs presents a significant challenge.
Solution
New Equilibrium Biosciences utilizes artificial intelligence to analyze biophysical data, enabling structure-based design in drug development. Their platform aims to identify potential molecular candidates more efficiently than traditional methods. By leveraging AI, the company seeks to streamline the drug discovery process, reducing both time and cost. The technology analyzes complex biophysical interactions to predict the efficacy and safety of drug candidates. This approach allows for a more targeted and informed selection of molecules for further development.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in drug discovery and development.
Features
- AI-driven analysis of biophysical data
- Structure-based design for drug development
- Efficient identification of potential molecular candidates